您当前位置:Therapeutic Advances in Medical Oncology期刊投稿发表详细信息
Therapeutic Advances in Medical Oncology

Therapeutic Advances in Medical Oncology Q2

  • 期刊收录:
  • SCIE
  • Scopus
  • DOAJ
基本信息
  • 期刊ISSN:

    1758-8340

  • 期刊简拼:

    THER ADV MED ONCOL

  • 年发文章数:

    194

  • E-ISSN:

    1758-8359

  • Gold OA文章占比

    89.69%

  • 研究文章占比:

    55.15%

  • 是否OA:

    Yes

  • Jcr分区:

    Q2

  • 中科院分区:

    2区

出版信息
  • 出版商:

    SAGE Publications Inc.

  • 涉及研究方向:

    ONCOLOGY-

  • 出版国家:

    ENGLAND

  • 出版语言:

    English

  • 出版周期:

    Continuous publication

  • 出版年份:

    2009

  • 2023-2024最新影响因子:4.3
  • 自引率:2.30%
  • 五年影响因子:4.9
  • JCI期刊引文指标:0.81
  • h-index:34
  • CiteScore:8.20

期刊简介

Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

The journal adheres to a blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.

《Therapeutic Advances in Medical Oncology》期刊已被查看:

此期刊被最新的JCR期刊SCIE收录

期刊信息

  • 通讯地址
  • SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP
  • 中国科学院《国际期刊预警名单(试行)》名单
  • 2024年02月发布的2024版:不在预警名单中
    2023年01月发布的2023版:不在预警名单中
    2021年12月发布的2021版:不在预警名单中
    2020年12月发布的2020版:不在预警名单中
    此期刊被最新的JCR期刊SCIE收录
  • 审稿速度
  • 收录数据库
  • 是否oa
  • 研究方向
  • 15 Weeks
  • SCIE,Scopus,DOAJ
  • Yes
  • ONCOLOGY-

分区信息

中科院分区
  • 大类学科
  • 分区
  • 小类学科
  • Top期刊
  • 综述期刊
  • 医学
  • 2区
  • ONCOLOGY
    肿瘤学
WOS分区等级:2区
  • 版本
  • 按学科
  • 分区
  • 影响因子
  • WOS期刊SCI分(2023-2024年最新版)
  • ONCOLOGY
  • Q2
  • 4.3
IF值(影响因子)趋势图
年发文量趋势图
自引率趋势图
中科院分区

常见问题

Therapeutic Advances in Medical Oncology相关文章